{"id":"https://openalex.org/W2005607780","doi":"https://doi.org/10.3899/jrheum.140288","title":"Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab","display_name":"Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab","publication_year":2015,"publication_date":"2015-02-15","ids":{"openalex":"https://openalex.org/W2005607780","doi":"https://doi.org/10.3899/jrheum.140288","mag":"2005607780","pmid":"https://pubmed.ncbi.nlm.nih.gov/25684767"},"language":"en","primary_location":{"id":"doi:10.3899/jrheum.140288","doi":"https://doi.org/10.3899/jrheum.140288","is_oa":true,"landing_page_url":"https://doi.org/10.3899/jrheum.140288","pdf_url":"https://www.jrheum.org/content/jrheum/42/4/712.full.pdf","source":{"id":"https://openalex.org/S50602745","display_name":"The Journal of Rheumatology","issn_l":"0315-162X","issn":["0315-162X","1499-2752"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320417","host_organization_name":"The Journal of Rheumatology Publishing Company Limited","host_organization_lineage":["https://openalex.org/P4310320417"],"host_organization_lineage_names":["The Journal of Rheumatology Publishing Company Limited"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.jrheum.org/content/jrheum/42/4/712.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110182317","display_name":"Shumpei Yokota","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4210153031","display_name":"Jichi Medical University Hospital","ror":"https://ror.org/04at0zw32","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210153031"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shumpei Yokota","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Chugai Pharmaceutical Co. Ltd., Tokyo","Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama","Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences","Department of Pediatrics, Nippon Medical School","Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa","Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, \nJapan","From The Safety Evaluation Committee of Tocilizumab for JIA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co. Ltd., Tokyo","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama","institution_ids":["https://openalex.org/I4210132452","https://openalex.org/I8588240"]},{"raw_affiliation_string":"Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences","institution_ids":["https://openalex.org/I125602781"]},{"raw_affiliation_string":"Department of Pediatrics, Nippon Medical School","institution_ids":["https://openalex.org/I80188885"]},{"raw_affiliation_string":"Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa","institution_ids":["https://openalex.org/I89630735"]},{"raw_affiliation_string":"Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, \nJapan","institution_ids":["https://openalex.org/I146500386","https://openalex.org/I4210153031"]},{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039313609","display_name":"Yasuhiko Itoh","orcid":"https://orcid.org/0000-0002-4999-6473","observed_orcids":["https://orcid.org/0000-0002-4999-6473"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasuhiko Itoh","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Department of Pediatrics, Nippon Medical School"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Department of Pediatrics, Nippon Medical School","institution_ids":["https://openalex.org/I80188885"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040707258","display_name":"Tomohiro Morio","orcid":"https://orcid.org/0000-0002-9259-1025","observed_orcids":["https://orcid.org/0000-0002-9259-1025"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomohiro Morio","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences","institution_ids":["https://openalex.org/I125602781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071873314","display_name":"Naokata Sumitomo","orcid":"https://orcid.org/0000-0001-7094-6772","observed_orcids":["https://orcid.org/0000-0001-7094-6772"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naokata Sumitomo","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Chugai Pharmaceutical Co., Ltd, Tokyo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Chugai Pharmaceutical Co., Ltd, Tokyo","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053031788","display_name":"Kaori Daimaru","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kaori Daimaru","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa;","institution_ids":["https://openalex.org/I89630735"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083901171","display_name":"Seiji Minota","orcid":"https://orcid.org/0000-0003-4084-6804","observed_orcids":["https://orcid.org/0000-0003-4084-6804"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]},{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]},{"id":"https://openalex.org/I4210132452","display_name":"Saitama International Medical Center","ror":"https://ror.org/03ftky336","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132452"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]},{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]},{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]},{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Seiji Minota","raw_affiliation_strings":["From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan.S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Med","institution_ids":["https://openalex.org/I125602781","https://openalex.org/I146500386","https://openalex.org/I4210132452","https://openalex.org/I4405254473","https://openalex.org/I80188885","https://openalex.org/I8588240","https://openalex.org/I89630735"]},{"raw_affiliation_string":"Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama","institution_ids":["https://openalex.org/I4210132452","https://openalex.org/I8588240"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.3859,"has_fulltext":true,"cited_by_count":103,"citation_normalized_percentile":{"value":0.97997958,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"42","issue":"4","first_page":"712","last_page":"722"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11892","display_name":"Kawasaki Disease and Coronary Complications","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/macrophage-activation-syndrome","display_name":"macrophage activation syndrome","score":1.0},{"id":"https://openalex.org/keywords/systemic-juvenile-idiopathic-arthritis","display_name":"systemic juvenile idiopathic arthritis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hemophagocytic-lymphohistiocytosis","display_name":"hemophagocytic lymphohistiocytosis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7229999899864197},{"id":"https://openalex.org/keywords/laboratory-markers","display_name":"laboratory biomarkers","score":0.7160000205039978},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.47099998593330383},{"id":"https://openalex.org/keywords/il-6-inhibition","display_name":"IL-6 inhibition","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.9709612727165222},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9514601230621338},{"id":"https://openalex.org/C2779613421","wikidata":"https://www.wikidata.org/wiki/Q6725504","display_name":"Macrophage activation syndrome","level":3,"score":0.9084151983261108},{"id":"https://openalex.org/C2779079688","wikidata":"https://www.wikidata.org/wiki/Q1642170","display_name":"Hemophagocytic lymphohistiocytosis","level":3,"score":0.6394280195236206},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.6096040606498718},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5638452172279358},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36093348264694214},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.22273188829421997},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001171","descriptor_name":"Arthritis, Juvenile","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D001171","descriptor_name":"Arthritis, Juvenile","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055501","descriptor_name":"Macrophage Activation Syndrome","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3899/jrheum.140288","doi":"https://doi.org/10.3899/jrheum.140288","is_oa":true,"landing_page_url":"https://doi.org/10.3899/jrheum.140288","pdf_url":"https://www.jrheum.org/content/jrheum/42/4/712.full.pdf","source":{"id":"https://openalex.org/S50602745","display_name":"The Journal of Rheumatology","issn_l":"0315-162X","issn":["0315-162X","1499-2752"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320417","host_organization_name":"The Journal of Rheumatology Publishing Company Limited","host_organization_lineage":["https://openalex.org/P4310320417"],"host_organization_lineage_names":["The Journal of Rheumatology Publishing Company Limited"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Rheumatology","raw_type":"journal-article"},{"id":"pmid:25684767","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25684767","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.3899/jrheum.140288","doi":"https://doi.org/10.3899/jrheum.140288","is_oa":true,"landing_page_url":"https://doi.org/10.3899/jrheum.140288","pdf_url":"https://www.jrheum.org/content/jrheum/42/4/712.full.pdf","source":{"id":"https://openalex.org/S50602745","display_name":"The Journal of Rheumatology","issn_l":"0315-162X","issn":["0315-162X","1499-2752"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320417","host_organization_name":"The Journal of Rheumatology Publishing Company Limited","host_organization_lineage":["https://openalex.org/P4310320417"],"host_organization_lineage_names":["The Journal of Rheumatology Publishing Company Limited"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Rheumatology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2005607780.pdf","grobid_xml":"https://content.openalex.org/works/W2005607780.grobid-xml"},"referenced_works_count":44,"referenced_works":["https://openalex.org/W1806733851","https://openalex.org/W1873141185","https://openalex.org/W1967868228","https://openalex.org/W1971308765","https://openalex.org/W1972041363","https://openalex.org/W1978089430","https://openalex.org/W1983067071","https://openalex.org/W1985121550","https://openalex.org/W1985586723","https://openalex.org/W1986945220","https://openalex.org/W1987026896","https://openalex.org/W1994860638","https://openalex.org/W1999622952","https://openalex.org/W2000155751","https://openalex.org/W2007836919","https://openalex.org/W2017213437","https://openalex.org/W2026404803","https://openalex.org/W2029127089","https://openalex.org/W2040397111","https://openalex.org/W2059117206","https://openalex.org/W2059766682","https://openalex.org/W2062603648","https://openalex.org/W2062885812","https://openalex.org/W2069208274","https://openalex.org/W2070086022","https://openalex.org/W2070409735","https://openalex.org/W2087769239","https://openalex.org/W2094071627","https://openalex.org/W2110029891","https://openalex.org/W2119120508","https://openalex.org/W2119893731","https://openalex.org/W2120852203","https://openalex.org/W2123289598","https://openalex.org/W2134389576","https://openalex.org/W2145389715","https://openalex.org/W2165127856","https://openalex.org/W2215566856","https://openalex.org/W2328314553","https://openalex.org/W2400002659","https://openalex.org/W2415334169","https://openalex.org/W2417195177","https://openalex.org/W2498168571","https://openalex.org/W4255497843","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2034353207","https://openalex.org/W3000292609","https://openalex.org/W3095970872","https://openalex.org/W2950789137","https://openalex.org/W2951893602","https://openalex.org/W2334078296","https://openalex.org/W2093580598","https://openalex.org/W2040414203","https://openalex.org/W2170289818","https://openalex.org/W4206001719"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"identify":[2],"macrophage":[3],"activation":[4],"syndrome":[5,75],"(MAS)":[6],"in":[7,29,44,79,133,141,148,156,169,183,209,213,222,234,252],"patients":[8,30,39,65,83,162,192,214,223,244],"with":[9,31,40,66,193,215,224],"systemic":[10],"juvenile":[11],"idiopathic":[12],"arthritis":[13],"(sJIA)":[14],"undergoing":[15],"tocilizumab":[16],"(TCZ)":[17],"treatment,":[18],"and":[19,25,97,102,121,151,177,180,201,258],"to":[20,27,64,219,240],"confirm":[21],"laboratory":[22,103,202,210],"marker":[23],"changes":[24],"responses":[26],"treatment":[28],"MAS":[32,132,140,176,205,238,257],"receiving":[33],"TCZ.":[34],"METHODS:":[35],"In":[36,191],"Japan,":[37],"394":[38],"sJIA":[41],"were":[42,111,160,172,186,206,217,260],"registered":[43],"an":[45],"all-patient":[46],"registry":[47],"surveillance":[48],"of":[49,52,81,90,130,138,146,154,204,237,246,256],"TCZ":[50,56,248],"as":[51],"January":[53],"15,":[54],"2012.":[55],"(8":[57],"mg/kg)":[58],"was":[59,77],"administered":[60],"every":[61],"2":[62,144,149,161,165,167,181],"weeks":[63],"sJIA.":[67],"MAS,":[68,117,119,179,197],"hemophagocytic":[69,74],"lymphohistiocytosis,":[70],"or":[71,195],"Epstein-Barr":[72],"virus-associated":[73],"(EB-VAHS)":[76],"reported":[78],"23":[80],"these":[82,95],"(25":[84],"events).":[85],"The":[86,124],"Safety":[87],"Evaluation":[88],"Committee":[89],"Tocilizumab":[91],"for":[92],"JIA":[93],"reviewed":[94],"cases":[96],"clinically":[98],"evaluated":[99],"the":[100,231,235,253],"data":[101,211],"findings":[104,203],"using":[105],"their":[106],"own":[107],"therapeutic":[108],"experience.":[109],"Events":[110],"categorized":[112],"into":[113,174,188],"4":[114],"groups:":[115],"definitive":[116,131,175,194],"probable":[118,139,178,189,196],"EB-VAHS,":[120],"non-MAS.":[122],"RESULTS:":[123],"committee's":[125],"review":[126],"revealed":[127],"3":[128,134],"events":[129,137,145,153,168,182],"patients,":[135,143,150],"12":[136],"11":[142],"EB-VAHS":[147,216,259],"8":[152,157],"non-MAS":[155],"patients.":[158],"There":[159],"who":[163],"developed":[164],"events:":[166],"1":[170],"patient":[171,185],"classified":[173,187],"another":[184],"MAS.":[190,225],"common":[198],"clinical":[199],"manifestations":[200],"observed.":[207],"Changes":[208],"observed":[212,221],"similar":[218,242],"those":[220],"CONCLUSION:":[226],"These":[227],"results":[228],"suggest":[229],"that":[230],"clinical/laboratory":[232],"features":[233],"course":[236],"appear":[239],"be":[241],"among":[243],"regardless":[245],"whether":[247],"is":[249],"administered.":[250],"Similarities":[251],"pathophysiological":[254],"background":[255],"also":[261],"suggested.":[262]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}